Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Dermatology"
DOI: 10.1001/jamadermatol.2017.4120
Abstract: Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine Paronychia and pseudopyogenic granuloma (pseudo-PG) are relatively common and difficult-to-manage adverse effects in patients undergoing treatment with… read more here.
Keywords: paronychia pseudopyogenic; factor receptor; topical timolol; growth factor ... See more keywords
Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2019.0063
Abstract: This medical record review investigates whether use of topical clindamycin and/or oral tetracyclines during management of epidermal growth factor receptor (EGFR) inhibitor–related papulopustular eruption is associated with antibiotic-resistant bacterial infection. read more here.
Keywords: related papulopustular; factor receptor; growth factor; papulopustular eruption ... See more keywords
New [1,2,4]triazolo[4,3‐c]quinazoline derivatives as vascular endothelial growth factor receptor‐2 inhibitors and apoptosis inducers: Design, synthesis, docking, and antiproliferative evaluation
Sign Up to like & getrecommendations! Published in 2022 at "Archiv der Pharmazie"
DOI: 10.1002/ardp.202200133
Abstract: In continuation of our previous efforts in the field of design and synthesis of vascular endothelial growth factor receptor (VEGFR)‐2 inhibitors, a new series of [1,2,4]triazolo[4,3‐c]quinazoline derivatives were designed and synthesized as modified analogs of… read more here.
Keywords: design synthesis; compound; endothelial growth; factor receptor ... See more keywords
Engineering soluble artificial epidermal growth factor receptor mimics capable of spontaneous in vitro dimerization
Sign Up to like & getrecommendations! Published in 2020 at "Biotechnology and Bioengineering"
DOI: 10.1002/bit.27659
Abstract: Epidermal growth factor receptor (EGFR) is a clinically validated target for a multitude of human cancers. The receptor is activated upon ligand binding through a critical dimerization step. Dimerization can be replicated in vitro by… read more here.
Keywords: dimerization; kinase; factor receptor; growth factor ... See more keywords
Proteomics identifies EGF‐like domain multiple 7 as a potential therapeutic target for epidermal growth factor receptor‐positive glioma
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Communications"
DOI: 10.1002/cac2.12092
Abstract: Glioma, the most frequent primary tumor of the central nervous system, has poor prognosis. The epidermal growth factor receptor (EGFR) pathway and angiogenesis play important roles in glioma growth, invasion, and recurrence. The present study… read more here.
Keywords: glioma; factor receptor; growth factor; epidermal growth ... See more keywords
Real‐world treatment patterns of metastatic non‐small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4918
Abstract: Several epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) have been approved for first‐line (1L) treatment of EGFR‐mutated metastatic non‐small cell lung cancer (mNSCLC) in the United States (US). Real‐world analyses of 1L treatment… read more here.
Keywords: receptor tyrosine; epidermal growth; factor receptor; growth factor ... See more keywords
In‐depth proteomics reveals the characteristic developmental profiles of early lung adenocarcinoma with epidermal growth factor receptor mutation
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5766
Abstract: Lung adenocarcinoma progresses stepwise from atypical adenomatous hyperplasia to adenocarcinoma in situ (AIS), followed by minimally invasive adenocarcinoma (MIA), and then obvious invasive adenocarcinoma. In this study, we examined the protein expression profiles of early… read more here.
Keywords: lung adenocarcinoma; epidermal growth; factor receptor; profiles early ... See more keywords
TAS‐120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
Sign Up to like & getrecommendations! Published in 2019 at "ChemMedChem"
DOI: 10.1002/cmdc.201800719
Abstract: 1‐[(3S)‐3‐[4‐Amino‐3‐[2‐(3,5‐dimethoxyphenyl)ethynyl]‐1H‐pyrazolo[3,4‐d]pyrimidin‐1‐yl]‐1‐pyrrolidinyl]‐2‐propen‐1‐one (TAS‐120) is an irreversible inhibitor of the fibroblast growth factor receptor (FGFR) family, and is currently under phase I/II clinical trials in patients with confirmed advanced metastatic solid tumours harbouring FGFR aberrations. This inhibitor specifically… read more here.
Keywords: tas 120; fibroblast growth; growth factor; reactivity ... See more keywords
Twice weekly pulse and daily continuous‐dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.30990
Abstract: In a phase 1 study of pulse/continuous‐dose erlotinib, no patient had disease progression in the central nervous system (CNS). This expansion cohort of the phase 1 study tested the same regimen in a cohort of… read more here.
Keywords: mutant lung; continuous dose; factor receptor; growth factor ... See more keywords
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials
Sign Up to like & getrecommendations! Published in 2019 at "Cancer"
DOI: 10.1002/cncr.31784
Abstract: Limited data exist on the safety of using anti–human epidermal growth factor receptor 2 (HER2) targeted agents during pregnancy. To date, only retrospective studies have assessed the prognosis of patients with a pregnancy after prior… read more here.
Keywords: early breast; factor receptor; human epidermal; growth factor ... See more keywords
Chimeric antigen receptor‐modified T‐cell therapy for platelet‐derived growth factor receptor α‐positive rhabdomyosarcoma
Sign Up to like & getrecommendations! Published in 2020 at "Cancer"
DOI: 10.1002/cncr.32764
Abstract: New immunotherapeutic approaches are urgently needed for metastatic rhabdomyosarcoma, which is associated with poor survival and unsatisfactory treatment outcomes. Platelet‐derived growth factor receptor α (PDGFRA) plays an essential role in the onset and development of… read more here.
Keywords: growth factor; rhabdomyosarcoma; receptor; factor receptor ... See more keywords